China Sinopharm chief rules out high price for coronavirus vaccine | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
May 29, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, MAY 29, 2025
China Sinopharm chief rules out high price for coronavirus vaccine

Coronavirus chronicle

Reuters
18 August, 2020, 06:25 pm
Last modified: 18 August, 2020, 06:26 pm

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • Children aged 5-11 to get Covid jabs from 11 August

China Sinopharm chief rules out high price for coronavirus vaccine

Sinopharm has said its experimental vaccine could be ready for public use by the end of this year. It has entered a late-stage human test in the United Arab Emirates to gather proof of efficacy for final regulatory approvals

Reuters
18 August, 2020, 06:25 pm
Last modified: 18 August, 2020, 06:26 pm
FILE PHOTO: The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong, China March 29, 2016. REUTERS/Bobby Yip/File Photo
FILE PHOTO: The company logo of Sinopharm Group Co Ltd is displayed at a news conference on the company's annual results in Hong Kong, China March 29, 2016. REUTERS/Bobby Yip/File Photo

A potential coronavirus vaccine being developed by a unit of China National Pharmaceutical Group (Sinopharm) could cost no more than 1,000 yuan ($144.27) for two shots, state media on Tuesday quoted chairman Liu Jingzhen as saying.

Sinopharm has said its experimental vaccine could be ready for public use by the end of this year. It has entered a late-stage human test in the United Arab Emirates to gather proof of efficacy for final regulatory approvals.

"It will not be priced very high. It is expected to cost a few hundred yuan for a shot, and for two shots it should be less than 1,000 yuan," Liu told the Guangming Daily newspaper.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Governments and drugmakers around the world are in a frenetic race to develop a Covid-19 vaccine. More than 200 candidates are in development, including more than 20 in human clinical trials.

Moderna Inc said earlier this month that smaller volumes of its experimental vaccine have been priced at $32-$37 per dose.

Last month, the US government struck a deal for an experimental vaccine being developed by Pfizer and partner BioNTech SE that secures enough to innoculate 50 million Americans for about $40 a person.

Sinopharm's Liu did not mention whether China's state-backed nationwide insurance program would cover some of the vaccine costs for consumers, or whether it could be included in the country's free vaccination scheme.

China National Biotec Group (CNBG), a Sinopharm unit, has moved two vaccine strains using the same method into human trials. Its plants in Wuhan and Beijing combined could make over 200 million doses of the drug annually.

($1 = 6.9316 Chinese yuan renminbi)

Sinopharm / covid-19 vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • BNP Chairperson Khaleda Zia virtually addressing an event on 29 May 2025, marking the death anniversary of BNP founder and former president Ziaur Rahman. Photo: Screengrab from BNP Media Cell video.
    Democracy still being obstructed at every step: Khaleda Zia
  • Bangladesh Engineering Industry Owners’ Association President Md Abdur Razzaque speaking at the inauguration ceremony of the Bangladesh Light Engineering Expo 2025 in Dhaka on 29 May 2025. Photo: TBS
    Like leather, light engineering sector also needs industrial park: Industry leaders
  • Representational Photo: TBS
    Deep depression halts cargo unloading at Chattogram Port's outer anchorage

MOST VIEWED

  • Dhaka areas at a gridlock on Wednesday, 28 May 2025. Photo: Syed Zakir Hossain/TBS
    BNP, Jamaat rallies: Traffic clogs Dhaka roads, including Motijheel, Paltan, Dainik Bangla intersection
  • IFIC Bank receives Tk6,000 cr in new deposits in six months
    IFIC Bank receives Tk6,000 cr in new deposits in six months
  • Mohammad Abdul Mannan, chairman FSIB Ltd. Sketch: TBS
    FSIB to bounce back soon
  • Abdul Awal Mintoo, chairman of National Bank Limited. Sketch: TBS
    'Regulatory support must for National Bank to restore depositors' confidence'
  • Md Nazrul Islam Swapan, chairman of EXIM Bank. Sketch: TBS
    Exim Bank restored depositors’ confidence, overcoming challenges
  • Mohammad Mamdudur Rashid, managing director and CEO, UCB. Sketch: TBS
    Customers’ trust and confidence fueling deposit growth at UCB

Related News

  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match
  • Children aged 5-11 to get Covid jabs from 11 August

Features

For hundreds of small fishermen living near this delicate area, sustainable fishing is a necessity for their survival. Photo: Syed Zakir Hossain

World Ocean Day: Bangladesh’s ‘Silent Island’ provides a fisheries model for the future

2h | The Big Picture
The university will be OK. But will the US? Photo: Bloomberg

A weaker Harvard is a weaker America

2h | Panorama
The Botanical Garden is a refuge for plant species, both native and exotic. Photo: Mehedi Hasan/TBS

The hidden cost of 'development' in the Botanical Garden

2h | Panorama
Stillbirths in Bangladesh: A preventable public health emergency

Stillbirths in Bangladesh: A preventable public health emergency

2h | Panorama

More Videos from TBS

News of The Day, 29 MAY 2025

News of The Day, 29 MAY 2025

1h | TBS News of the day
Businesses set for relief as interim govt eyes major tax & fine cuts

Businesses set for relief as interim govt eyes major tax & fine cuts

4h | TBS Insight
Love is essential for human life

Love is essential for human life

3h | TBS Programs
What Should Be the Interim Government’s Budget Priority?

What Should Be the Interim Government’s Budget Priority?

2h | TBS Economy
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net